why choose us

First received: May 23, 2023

Clinical Trial: RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL

Study Status: Completed

Recruit Status: RECRUITING

Condition: Neoplasms

Study Type: INTERVENTIONAL


Official Title: Efficacy, Safety and Cytopharmacokinetics of RD13-02 Cell Injection in the Treatment of Patients With Recurrent or Refractory CD7-positive Hematologic Malignancies

Brief Summary: This is a single-arm, open-label, single-center, phase I study.The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL, and to evaluate the pharmacokinetics of CD7 CAR-T in patients.

Read more